<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00222105</url>
  </required_header>
  <id_info>
    <org_study_id>Doxil</org_study_id>
    <nct_id>NCT00222105</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life</brief_title>
  <official_title>Doxil® (Pegylated Liposomal Doxorubicin), Dexamethasone Plus Thalidomide (Ddt) in Previously Untreated Multiple Myeloma: A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Four monthly treatments with pegylated liposomal doxorubicin, thalidomide and dexamethasone
      for newly diagnosed myeloma patients as induction therapy prior to high dose chemotherapy and
      autologous stem cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple myeloma (MM) is an incurable hematological malignancy of plasma cell origin. Plasma
      cell clonality and dysfunctional immunoglobulin production characterize the disease. The
      consequences of abnormal plasma cell growth are manifested by a myriad of symptoms and signs
      that often have significant impact on the patient's quality of life. These include
      pancytopenia secondary to predominant distribution of tumor cells within the bone marrow
      along with many other effects.

      This study is focused on the efficacy of Doxil® (pegylated liposomal doxorubicin) with low
      dose Dexamethasone and Thalidomide (Ddt) in previously untreated patients with multiple
      myeloma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>At End of Cycle 1, 28 Days</time_frame>
    <description>Response rate after completion of first cycle. Measured as the proportion of subjects who have a partial response (PR) or complete response (CR), represented as the overall response rate (ORR). SWOG/IBMTR (Southwest Oncology Group/International Blood and Marrow Transplant Research) criteria utilized to determine multiple myeloma response rates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>End of study, up to 12 months</time_frame>
    <description>Count of Participants with adverse events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxil, Thalidomide, Dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxil</intervention_name>
    <description>Doxil 40 mg/m2 IV day 1</description>
    <arm_group_label>1</arm_group_label>
    <other_name>pegylated liposomal doxorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>50-100 mg day 1-28</description>
    <arm_group_label>1</arm_group_label>
    <other_name>thalidomid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 40 mg day 1-4 and 15-18</description>
    <arm_group_label>1</arm_group_label>
    <other_name>decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with active, symptomatic multiple myeloma without prior chemotherapy:

          -  Durie-Salmon Stage II-III A/B

          -  Stage I patients with at least 2 of the poor prognostic indicators may be eligible.

          -  Patients with plasma cell leukemia

          -  Non-secretory multiple myeloma patients are eligible

          -  Patients between the ages of 18 and 75 years old

          -  Female Patients of child bearing age (up to age 50) who are not pregnant and agree to
             use two adequate birth control methods during the study and at least six months after
             treatment unless patient has undergone hysterectomy or has been in menopause for 2
             years.

          -  Patients with Southwest Oncology Group (SWOG) performance status of 3 or better

          -  Patients who have received prior lower dose Dexamethasone Therapy (ie. 4 mg QID) as
             adjunct to radiation therapy for cord compression may be eligible

          -  All patients must have a MUGA scan indicating a left ventricular ejection fraction
             (LVEF) of greater than or equal to 50% within 42 days prior to registration

          -  Must be able to understand English.

          -  Must be willing and eligible to sign up for the STEPS program

        Exclusion Criteria:

          -  Nursing mothers or women who are pregnant

          -  Patients with a history of hypersensitivity reaction to doxorubicin or agents in
             Doxil®

          -  Patients with previous malignancies at other sites except surgically treated
             nonmelanomatous skin cancers, prostate cancer or superficial cervical cancers, or
             other cancer from which the patient had been disease free for 5 or more years.

          -  History of mediastinal radiation for any reason

          -  History of receiving prior anthracyclines

          -  Patients with uncontrolled medical problems such as diabetes mellitus, cardiac,
             pulmonary, hepatic, and renal diseases unless renal insufficiency is felt to be
             secondary to multiple myeloma

          -  Myocardial infarction within 6 months of enrollment in the study.

          -  Major surgery within 4 weeks of enrollment.

          -  Patients previously treated or receiving other treatment for multiple myeloma other
             than lower doses dexamethasone as adjunct to radiotherapy

          -  Pre-existing peripheral neuropathy

          -  Patients with previously diagnosed malabsorption syndromes or anatomical abnormalities
             of the gastrointestinal tract that result in malabsorption syndromes.

          -  Patients with a history of cardiac disease, defined as New York Heart Association
             Class II or greater, or clinical evidence of congestive heart failure.

          -  Patients with psychiatric or central nervous systems disorders interfering with
             compliance of orally administered medication.

          -  Patients currently receiving anticoagulant therapy for venous thromboembolic episode
             or other hypercoagulable states.

          -  Patients who are unable to understand the English language.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Delva Deauna-Limayo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>March 21, 2017</results_first_submitted>
  <results_first_submitted_qc>March 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2017</results_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1</title>
          <description>Doxil, Thalidomide, Dexamethasone
Doxil: Doxil 40 mg/m2 IV day 1
Thalidomide: 50-100 mg day 1-28
Dexamethasone: Dexamethasone 40 mg day 1-4 and 15-18</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Removed due to wrong diagnosis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment delays</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>Doxil, Thalidomide, Dexamethasone
Doxil: Doxil 40 mg/m2 IV day 1
Thalidomide: 50-100 mg day 1-28
Dexamethasone: Dexamethasone 40 mg day 1-4 and 15-18</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="49" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate</title>
        <description>Response rate after completion of first cycle. Measured as the proportion of subjects who have a partial response (PR) or complete response (CR), represented as the overall response rate (ORR). SWOG/IBMTR (Southwest Oncology Group/International Blood and Marrow Transplant Research) criteria utilized to determine multiple myeloma response rates.</description>
        <time_frame>At End of Cycle 1, 28 Days</time_frame>
        <population>Five subjects did not complete first cycle.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Doxil, Thalidomide, Dexamethasone
Doxil: Doxil 40 mg/m2 IV day 1
Thalidomide: 50-100 mg day 1-28
Dexamethasone: Dexamethasone 40 mg day 1-4 and 15-18</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Response rate after completion of first cycle. Measured as the proportion of subjects who have a partial response (PR) or complete response (CR), represented as the overall response rate (ORR). SWOG/IBMTR (Southwest Oncology Group/International Blood and Marrow Transplant Research) criteria utilized to determine multiple myeloma response rates.</description>
          <population>Five subjects did not complete first cycle.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity</title>
        <description>Count of Participants with adverse events.</description>
        <time_frame>End of study, up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Doxil, Thalidomide, Dexamethasone
Doxil: Doxil 40 mg/m2 IV day 1
Thalidomide: 50-100 mg day 1-28
Dexamethasone: Dexamethasone 40 mg day 1-4 and 15-18</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity</title>
          <description>Count of Participants with adverse events.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>Doxil, Thalidomide, Dexamethasone
Doxil: Doxil 40 mg/m2 IV day 1
Thalidomide: 50-100 mg day 1-28
Dexamethasone: Dexamethasone 40 mg day 1-4 and 15-18</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cancer Center Clinical Trials Office</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>(913) 945-5059</phone>
      <email>SWILLIAM@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

